Novartis hails single-dose H1N1 success

Racing to produce a huge quantity of vaccine to guard against an expected tsunami of swine flu cases this fall, Novartis says that a single low dose of its Celtura jab produced an immune response sufficient to protect the volunteers enrolled in a small trial. The cell culture-based vaccine was tested in a small trial involving 100 people, says the giant pharma manufacturer. Researchers are now studying Celtura in trials involving 6,000 people. FierceVaccines

Suggested Articles

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.

Five Prime Therapeutics’ clinical development lead is hoping for a more stable time at new employer Spectrum Pharma.

The update comes as Gilead closes in on a FDA approval that will position it to compete with JAK inhibitors sold by AbbVie, Eli Lilly and Pfizer.